L’étude sur le TH1902 de Theratechnologies publiée dans la revue Pharmaceutics montre une inhibition de la croissance des cellules de type souches cancéreuses humaines du cancer de l’ovaire et du CSTN exprimant le récepteur de la sortiline (SORT1) et de la croissance tumorale Les chercheurs signalent une activité anticancéreuse supérieure contre les cellules de type souches cancéreuses avec le TH1902, comparativement au docétaxel non conjugué.Premières données probantes...

Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Researchers report superior anticancer activity against cancer stem-like cells with TH1902, compared to unconjugated docetaxelFirst evidence for TH1902 targeting of human breast and ovarian cancer...

Cancer Antibody Drug Conjugate Market 2028 Delhi, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Global Cancer Antibody Drug Conjugate Market, Drug Sales, Price, & Clinical Trials Insight 2028 Report Highlights: Global Cancer Antibody Drug...

Vaccines Market value to hit $72.5 billion by 2025: Global Market Insights, Inc. Selbyville, Delaware, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Global Market Insights, Inc., announces a research report on ‘Vaccines Market Trends and Forecast 2019-2025’. The report covers an extensive...

Global Vaccines Market to surpass $65 Bn by 2024: Global Market Insights, Inc. Sellbyville, Delaware, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Global Vaccines Market  is poised to cross USD 65 billion by 2024; according to a new research report by Global Market Insights, Inc....